Clozapine-induced liver injury and pleural effusion


Published in:
Mental illness

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2014 the authors.
This is an open access Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Clozapine-induced liver injury and pleural effusion

Joseph P.M. Kane, Francis A. O’Neill
Centre for Public Health, Institute of Clinical Sciences, Queens University Belfast Royal Victoria Hospital, UK

Abstract

Clozapine, whilst associated commonly with a transient and benign increase in liver enzymes, has also been associated with varying presentations of hepatitis in existing case reports. This report describes what we believe to be the first documented case of acute liver injury and pleural effusion associated with clozapine, resolving after cessation of the agent. The case supports existing literature in advocating a high index of suspicion, particularly in the 4-5 weeks following clozapine initiation, when considering nonspecific clinical symptoms and signs.

Introduction

Clozapine is an atypical antipsychotic and a highly effective agent in the management of treatment-resistant schizophrenia. Whilst associated commonly with a transient and benign increase in liver enzymes, it also lists hepatitis amongst its side effects. Existing case studies report a wide variation in comorbidity characteristics and biochemical profiles of such presentations. In this case study we describe a case of clozapine-induced hepatotoxicity with associated pleural effusion.

Case Report

Ms. A, a 47-year-old woman with a long-standing diagnosis of schizophrenia, was commenced on clozapine therapy having suffered a relapse characterized by an escalation in auditory hallucinations, persecutory thought, behavioral disturbance and negative symptoms; treatment with both atypical (olanzapine, risperidone) and typical (haloperidol) antipsychotic agents had been unsuccessful. No significant medical disorders were present in the patient’s past medical history or family history, nor was there a history of drug allergies. There was no history of alcohol or illicit drug abuse. She described a smoking history of 30 pack years. Baseline electrocardiograph and blood tests, including liver function tests (LFTs), full blood count, fasting lipid profile and glucose, were all unremarkable.

Daily clozapine dose was titrated to 400 mg over a three week period with mild sedation alone noted as a side effect. A tangible improvement in MsA’s mental state was noted over this period, with improvement in both positive and negative symptoms.

Thirty days following clozapine prescription, the patient developed lethargy and pyrexia, cough and left basal crepitations. Blood investigations revealed an elevated white cell count (WCC 14.4×10⁹/L), characterized by eosinophilia (2.39×10⁹/L), and elevated C reactive protein (CRP). LFTs returned deranged values of bilirubin 23 umol/L (normal range 3-18 umol/L), alkaline phosphatase (ALP) 220 U/L (n.r. 35-120 U/L), aspartate transaminase (AST) 338 U/L (n.r. 4-32), gamma-glutamyl transpeptidase (GGT) 96 U/L (n.r. 12.58 U/L), and alanine transaminase (ALT) 894 U/L (n.r. 10-35 U/L).

Symptoms persisted for several days, during which chest X-ray indicated the presence of a small left basal effusion. Although initially diagnosed as a lower respiratory chest infection and treated with Co-amoxiclav, clarithromycin, and subsequently piperacillin/tazobactam, all antibiotic agents were discontinued seven days after onset of symptoms when concern arose that the agents were both ineffective and contributing to LFT derangement.

Abdominal ultrasound was normal, while copper and caeruloplasmin levels were within reference ranges. Hepatitis A, B, C and E serology tests were negative, as were CMV and EBV serology. Levels of serum immunoglobulins (ANAs), anti-smooth muscle antibodies (ASMA), anti-liver-kidney microsome-1 antibodies (ALKM-1) and anti-liver cytosol antibody-1 (ALC-1) were within reference ranges and serum paracetamol levels were measured at less than 0.1 mmol/L. Whilst magnetic resonance imaging studies and pleural effusion aspiration were scheduled, these were precluded by the patient withholding her consent to undergo these investigations.

The patient deteriorated clinically over the following days, developing jaundice and persisting lethargy. Liver enzymes reached peak values of bilirubin 86 umol/L, ALP 406 U/L, AST 569 U/L, GGT 173 U/L, and ALT 707 U/L before clozapine was discontinued, 40 days following initial prescription. Liver enzymes reduced markedly by two days after cessation, returning to within normal reference ranges within six weeks. All evidence of pleural effusion had disappeared from chest X-ray within two days of clozapine cessation.

Discussion and Conclusions

We report a case of drug-induced liver injury with pleural effusion as a side effect of clozapine therapy. Although transient LFT elevation is well recognized in the period following clozapine prescription, liver injury is a rare side effect of clozapine therapy; to date only five cases of mortality secondary to hepatic failure associated with clozapine therapy have been reported in the United Kingdom. Current guidelines, however, advocate routine LFT monitoring only at baseline and every six months following prescription.

Other cases of drug-induced liver injury have been described in the existing literature, though none with associated pleural effusion. Whilst Thompson et al. describe a case involving hepatitis and bilateral pleural effusion, together with hematura and proteinuria, insult was of an obstructive, rather than hepatocellular mechanism, and symptoms occurred far earlier in the course of treatment (18 days). Two distinct mechanisms for such reactions arise from the documented cases. Ms. A’s eosinophilia and elevated inflammatory markers suggest an etiology more closely aligned to the immunoinflammatory reaction observed in approximately half of the cases documented, than with the idiosyncratic responses described in the remainder. Our case is comparable with other reported cases of liver toxi-
city in onset of symptoms (4-5 weeks following clozapine initiation), clozapine dose (300-500 mg daily) and duration before normalization of laboratory results (4-6 weeks), although the LFT figures reported in Ms. A’s case surpass those described in existing literature. It should be noted that in many of these cases, clinical symptoms were non-specific, as in Ms. A’s case, or absent altogether.

The authors fully acknowledge that the patient’s pleural effusion may have occurred due to other etiologies, an assertion that may have been supported by investigations declined by Ms. A. We do, however, believe that the close correlation of clinical symptoms with laboratory tests and the rapid resolution of effusion in the absence of antibiotic therapy support an association with hepatotoxicity. It is also noted that clozapine-induced pleural effusion is not unprecedented in the literature.

Whilst both the unsuccessful and successful re-challenges with clozapine therapy following adverse reactions are documented in existing reports, re-challenge was considered inappropriate in Ms. A’s case, given the extent of LFT derangement and clinical symptoms.

This case supports existing literature in advocating a high index of suspicion, particularly in the 4-5 weeks following clozapine initiation, when considering clinical symptoms and signs commonly associated with other pathologies. Whilst the documented prevalence of transient LFT elevation should urge caution in the premature cessation of clozapine therapy, clinicians should maintain a low threshold for monitoring such parameters following the emergence of innocuous symptoms and signs.

### References